Harleysville, PA, United States of America

Christopher D Cox

USPTO Granted Patents = 38 (Patent Applications = 6)

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 24 (Patent Applications = 25)

Average Co-Inventor Count = 3.9

ph-index = 11

Forward Citations = 403(Granted Patents)

Location History:

Harrison City, PA (US) (2001)
Harelysville, PA (US) (2013 - 2014)
Harleysville, PA (US) (2007 - 2016)

Company Filing History:

27 out of 2,405

Merck Sharp + Dohme Corp.

Merch Sharp & Dohme Ltd

patents

4. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2016

Loading Chart...

38 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 9428492 - Secondary alcohol substituted triazoles as PDE10 inhibitors (2016-08-30),

2. 9365562 - 1,3 substituted azetidine PDE10 inhibitors (2016-06-14),

3. 9266881 - Triazolopyridinone PDE10 inhibitors (2016-02-23),

4. 9200001 - Triazolyl PDE10 inhibitors (2015-12-01),

5. 9062059 - Pyrimidine PDE10 inhibitors (2015-06-23),

6. 8975261 - Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors (2015-03-10),

7. 8957077 - Pyrazolopyrimidine PDE 10 inhibitors (2015-02-17),

8. 8846000 - Radiolabeled PDE10 inhibitors (2014-09-30),

9. 8785467 - Alkoxy pyrimidine PDE10 inhibitors (2014-07-22),

10. 8710076 - 2,5-disubstituted piperidine orexin receptor antagonists (2014-04-29),

11. 8703770 - Pyridazine carboxamide orexin receptor antagonists (2014-04-22),

12. 8691827 - Amino tetrahydro-pyridopyrimidine PDE10 inhibitors (2014-04-08),

13. 8685961 - Diazepan orexin receptor antagonists (2014-04-01),

14. 8669272 - 2,5-disubstituted piperidine orexin receptor antagonists (2014-03-11),

15. 8618102 - Bridged diazepan orexin receptor antagonists (2013-12-31),

Title: Christopher D. Cox: Innovator in Therapeutic Agents for CNS Disorders

Introduction: Christopher D. Cox, based in Harleysville, PA, is an accomplished inventor with a significant impact in the field of pharmacology. With an impressive portfolio of 37 patents, he has dedicated his career to developing therapeutic agents that target central nervous system (CNS) disorders.

Latest Patents: Among his latest inventions are groundbreaking compounds aimed at treating various neurological and psychiatric disorders. One notable patent is for secondary alcohol substituted triazoles as PDE10 inhibitors, which are designed to be effective therapeutic agents for conditions like schizophrenia, psychosis, and Huntington's disease. Another innovative patent is focused on 1,3 substituted azetidine PDE10 inhibitors, which similarly target CNS disorders associated with phosphodiesterase 10 (PDE10). Both patents emphasize the treatment of disorders linked to striatal hypofunction and basal ganglia dysfunction.

Career Highlights: Christopher has made significant contributions through his roles at prominent pharmaceutical companies, including Merck Sharp & Dohme Corporation and Merck & Company, Inc. His work has been pivotal in advancing therapeutic strategies that tackle complex CNS challenges.

Collaborations: Throughout his career, Christopher has collaborated with esteemed colleagues, notably Paul J. Coleman and John D. Schreier. Their teamwork has fostered innovative solutions and propelled advancements in the treatment of CNS disorders.

Conclusion: Christopher D. Cox stands out as a key figure in the field of pharmacology, particularly for his innovative approach to addressing disorders of the central nervous system. His 37 patents underscore not only his expertise but also his commitment to improving the lives of those affected by neurological and psychiatric conditions. Through his work, he continues to inspire future advancements in therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.